Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of RDN-929 in Healthy Adults and Elderly
NCT03668314Phase 1Completed
- Sponsor
- Alkermes
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RDN-929 in Alzheimer's disease (AD), Parkinson's disease (PD) and frontotemporal dementia (FTD) (5 arms), sponsored by Alkermes. Primary endpoints: Number of subjects with adverse events up to 7 weeks, Number of subjects with Physical exam findings up to 7 weeks and 7 more. Started Oct 2018; status: completed.
02
Drugs
RDN-929
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT03668314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668314.